BioSpace News Archive

2seventy bio, Inc., a leading immuno-oncology cell therapy company, announced that the Phase 1 trial of the PLAT-08 study of SC-DARIC33 in Acute Myeloid Leukemia has been paused by Seattle Children’s, the Company’s partner and the regulatory sponsor of the study.

Standard BioTools Inc., driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – announced Company management will participate in the following investor conferences.

Blue Water Biotech, Inc., a biotechnology company spanning multiple sectors, announced the signing of an Asset Purchase Agreement with WraSer, LLC and Xspire Pharma, LLC for the purchase of six FDA-approved assets across multiple indications, including cardiology, otic infections, and pain management.

Surmodics, Inc., a leading provider of medical device and in vitro diagnostic technologies, announced it has received U.S. Food and Drug Administration 510 clearance for its Pounce™ LP Thrombectomy System.

Apyx Medical Corporation announced it has received 510 clearance from the U.S. Food and Drug Administration for the Renuvion Micro Handpiece, a new addition to the Renuvion product family.

Motus GI Holdings, Inc. announced that the Pure-Vu Gen 4 Gastro and Colon system was featured during the 9th Ecuadorian Institute of Digestive Diseases Live Endoscopy Course 2023 at the Pentax Learning Center, which is considered one of the most important digestive medicine annual events held in the Latin American region with over 1,000 physicians registered.

electroCore, Inc., a commercial-stage bioelectronic medicine and wellness company, announced that Company CEO, Dan Goldberger, will present at the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest.

MediWound Ltd. announced its participation in the upcoming Healthcare Virtual Conference Part II, organized by Maxim Group LLC and hosted by M-Vest.

Allogene Therapeutics, Inc., a clinical-stage biotechnology company pioneering the development of allogeneic CAR T products for cancer, announced that its Chief Financial Officer, Eric T. Schmidt, Ph.D., will step down from his position to spend more time with his family on the East Coast.

Enterome announces first clinical results from the Phase 1/2 trial of EO2463, an experimental treatment for indolent non-Hodgkin B cell lymphoma.